நிறுவனங்கள் ஹோல்டிங்ஸ் லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிறுவனங்கள் ஹோல்டிங்ஸ் லிமிடெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிறுவனங்கள் ஹோல்டிங்ஸ் லிமிடெட் Today - Breaking & Trending Today

China Gas plans $1.5b share sale for new gas projects, business development


China Gas plans $1.5b share sale for new gas projects, business development
FILE PHOTO: Gas storage facilities owned by China Gas Holdings are seen at a refueling station for ships in Chongqing, China December 12, 2017. REUTERS/Chen Aizhu
April 22, 2021
China Gas Holdings Ltd plans the sale of HK$11.66 billion ($1.50 billion) worth of new shares to major shareholders, to raise capital for gas projects and expansion.
It plans to acquire city gas projects in China, and expand and develop liquefied petroleum gas and distribution heating businesses.
The gas services provider has agreed to sell 392 million new shares, or 6.99% of the enlarged share capital, to shareholders Beijing Enterprises Holdings Ltd and China Gas Group Ltd, it said in a filing to the Hong Kong bourse on Thursday. ....

Hong Kong , Goldman Sachs Asia , China Gas Group Ltd , China Gas Holdings Ltd , Enterprises Holdings Ltd , China Gas Group , Ubs Ag , Beijing Enterprises Holdings Ltd , China Gas , Goldman Sachs , ஹாங் காங் , கோல்ட்மேன் சாக்ஸ் ஆசியா , சீனா வாயு ஹோல்டிங்ஸ் லிமிடெட் , நிறுவனங்கள் ஹோல்டிங்ஸ் லிமிடெட் , சீனா வாயு குழு , பெய்ஜிங் நிறுவனங்கள் ஹோல்டிங்ஸ் லிமிடெட் , சீனா வாயு , கோல்ட்மேன் சாக்ஸ் ,

Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies


Published: Feb 10, 2021
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/
 Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch s portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company s proprietary Engineered Thymic Niche (ETN) platform. The finan ....

British Columbia , Peter Zandstra , Mary Moynihan , David Chang , University Of Toronto , Enterprises Holdings Ltd , Allogene Therapeutics Inc , Sunnybrook Research Institute , Centre For Commercialization Of Regenerative Medicine , Prnewswire Notch Therapeutics Inc , Allogene Therapeutics , Lumira Ventures , Holdings Ltd , Regenerative Medicine , Casdin Capital , Samsara Biocapital , Engineered Thymic Niche , David Main , Chief Executive Officer , Notch Board , Notch Therapeutics , Toronto Innovation Acceleration Partners , Notch Therapeutics Closes 85 Million Seriesa Financing To Develop Pipeline Of Renewable Stem Cell Derived Cancer Immunotherapies , பிரிட்டிஷ் கொலம்பியா , மேரி மாய்நீஹாந் , டேவிட் சாங் ,